Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment

References

• BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• National Cancer Institute, Ministry of Health. Estatísticas de câncer. [Cancer Statistics]. https://www.inca.gov.br/numeros-de-cancer. Accessed 76, 2020. Portuguese.
   Google Scholar
• HammondMEH, HayesDF, DowsettM, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–e72. doi:10.1043/1543-2165-134.7.e4820586616
   PubMed Web of Science ®Google Scholar
• WolffAC, HammondMEH, HicksDG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. doi:10.1200/JCO.2013.50.998424101045
   PubMed Web of Science ®Google Scholar
• TriversKF, LundMJ, PorterPL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20(7):1071–1082. doi:10.1007/s10552-009-9331-119343511
   PubMed Web of Science ®Google Scholar
• ChiuAM, MitraM, BoymoushakianL, CollerHA. Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer. Sci Rep. 2018;8(1):1–14. doi:10.1038/s41598-018-29992-529311619
   PubMed Web of Science ®Google Scholar
• LehmannBD, BauerJA, ChenX, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767. doi:10.1172/JCI4501421633166
   PubMed Web of Science ®Google Scholar
• LehmannBD, JovanovićB, ChenX, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368. doi:10.1371/journal.pone.015736827310713
   PubMed Web of Science ®Google Scholar
• SantonjaA, Sánchez-MuñozA, LluchA, et al. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget. 2018;9(41):26406–26416. doi:10.18632/oncotarget.2541329899867
   PubMedGoogle Scholar
• IrvinWJ, CareyLA. What is triple-negative breast cancer?Eur J Cancer. 2008;44(18):2799–2805. doi:10.1016/j.ejca.2008.09.03419008097
   PubMed Web of Science ®Google Scholar
• WuQ, MaG, DengY, et al. Prognostic value of Ki-67 in patients with resected triple-negative breast cancer: a meta-analysis. Front Oncol. 2019;9. doi:10.3389/fonc.2019.01068
   Web of Science ®Google Scholar
• BhattaraiS, KlimovS, MittalK, et al. Prognostic role of androgen receptor in triple negative breast cancer: a multi-institutional study. Cancers. 2019;11(7):995. doi:10.3390/cancers11070995
   PubMed Web of Science ®Google Scholar
• PengY, ButtYM, ChenB, ZhangX, TangP. Update on immunohistochemical analysis in breast lesions. Arch Pathol Lab Med. 2017;141(8):1033–1051. doi:10.5858/arpa.2016-0482-RA28574279
   PubMed Web of Science ®Google Scholar
• Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification. GMR | Genetics and Molecular Research | The Original by FUNPEC-RP; 824, 2015https://www.geneticsmr.com/articles/4334. Accessed 429, 2020.
   Google Scholar
• Instituto Brasileiro de Gergrafia e Estatistica. Pesquisa das Características Étnico-Raciais da População - PCERP | 2008. [Survey of Ethnic-Racial Characteristics of the Population - PCERP | 2008 | IBGE]. https://www.ibge.gov.br/estatisticas/sociais/populacao/9372-caracteristicas-etnico-raciais-da-populacao.html?=&t=o-que-e. Accessed 1015, 2020. Portuguese.
   Google Scholar
• QuintyneKI, WoulfeB, CoffeyJC, MerriganA, GuptaRK. Lymph node ratio in sentinel lymph node biopsy era: are we losing prognostic information?Clin Breast Cancer. 2017;17(2):117–126. doi:10.1016/j.clbc.2016.07.01127592541
   PubMed Web of Science ®Google Scholar
• NahlehZ, SivasubramaniamD, DhaliwalS, SundarajanV, KomrokjiR. Residual cancer burden in locally advanced breast cancer: a superior tool. Curr Oncol. 2008;15(6):271–278. doi:10.3747/co.v15i6.24219079627
   PubMed Web of Science ®Google Scholar
• SajidMT, AhmedM, AzharM, et al. Age-related frequency of triple negative breast cancer in women. J Coll Physicians Surg Pak. 2014;24(6):400–403.24953912
   PubMed Web of Science ®Google Scholar
• DentR, TrudeauM, PritchardKI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–4434. doi:10.1158/1078-0432.CCR-06-304517671126
   PubMed Web of Science ®Google Scholar
• KeamB, ImS-A, LeeK-H, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011;13(2):R22. doi:10.1186/bcr283421366896
   PubMed Web of Science ®Google Scholar
• MatsubaraN, MukaiH, MasumotoM, et al. Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR. Breast Cancer Res Treat. 2014;147(1):95–102. doi:10.1007/s10549-014-3084-625106660
   PubMed Web of Science ®Google Scholar
• WangR-X, ChenS, JinX, ShaoZ-M. Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. Sci Rep. 2016;6. doi:10.1038/srep30091.
   Web of Science ®Google Scholar
• NielsenTO, HsuFD, JensenK, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367–5374. doi:10.1158/1078-0432.CCR-04-022015328174
   PubMed Web of Science ®Google Scholar
• Badowska-KozakiewiczAM, BudzikMP. Immunohistochemical characteristics of basal-like breast cancer. Contemp Oncol. 2016;20(6):436–443. doi:10.5114/wo.2016.56938
   Google Scholar
• RyuDW, JungMJ, ChoiWS, LeeCH. Clinical significance of morphologic characteristics in triple negative breast cancer. J Korean Surg Soc. 2011;80(5):301–306. doi:10.4174/jkss.2011.80.5.30122066052
   PubMedGoogle Scholar
• van de RijnM, PerouCM, TibshiraniR, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161(6):1991–1996. doi:10.1016/S0002-9440(10)64476-812466114
   PubMed Web of Science ®Google Scholar
• Abd El-RehimDM, PinderSE, PaishCE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203(2):661–671. doi:10.1002/path.155915141381
   PubMed Web of Science ®Google Scholar
• InancM, OzkanM, KaracaH, et al. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med Oncol Northwood Lond Engl. 2014;31(1):801. doi:10.1007/s12032-013-0801-7
   Web of Science ®Google Scholar
• BrotM, SoaresFA, StiepcichMMA, CúrcioVS, GobbiH. Basal-like breast carcinomas: clinicopathologic and evolutive profile. Rev Assoc Med Bras. 2009;55:529–534.19918651
   PubMed Web of Science ®Google Scholar
• SableM, PaiTD, ShetT, PatilA, DhanavadeS, DesaiSB. Triple-negative breast cancer: a comprehensive study of clinical, histomorphological, and immunohistochemical features in Indian patients. Int J Surg Pathol. 2017;25(3):230–237. doi:10.1177/106689691666781527612858
   PubMed Web of Science ®Google Scholar
• GluzO, LiedtkeC, GottschalkN, PusztaiL, NitzU, HarbeckN. Triple-negative breast cancer–current status and future directions. Ann Oncol. 2009;20(12):1913–1927. doi:10.1093/annonc/mdp49219901010
   PubMed Web of Science ®Google Scholar
• GumuskayaB, AlperM, HucumenogluS, AltundagK, UnerA, GulerG. EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer Genet Cytogenet. 2010;203(2):222–229. doi:10.1016/j.cancergencyto.2010.07.11821156237
   PubMedGoogle Scholar
• ParkHS, JangMH, KimEJ, et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol. 2014;27(9):1212–1222. doi:10.1038/modpathol.2013.25124406864
   PubMed Web of Science ®Google Scholar
• NakajimaH, IshikawaY, FuruyaM, et al. Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer. Breast Cancer Tokyo Jpn. 2014;21(1):66–74. doi:10.1007/s12282-012-0354-1
   PubMed Web of Science ®Google Scholar
• LiuD, HeJ, YuanZ, et al. EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol Northwood Lond Engl. 2012;29(2):401–405. doi:10.1007/s12032-011-9827-x
   Web of Science ®Google Scholar
• NiemeierLA, DabbsDJ, BeriwalS, StriebelJM, BhargavaR. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010;23(2):205–212. doi:10.1038/modpathol.2009.15919898421
   PubMed Web of Science ®Google Scholar
• HeJ, PengR, YuanZ, et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol Northwood Lond Engl. 2012;29(2):406–410. doi:10.1007/s12032-011-9832-0
   Web of Science ®Google Scholar
• WangC, PanB, ZhuH, et al. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis. Oncotarget. 2016;7(29):46482–46491. doi:10.18632/oncotarget.1020827374089
   PubMedGoogle Scholar
• QuQ, MaoY, FeiX, ShenK. The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS One. 2013;8(12):e82650. doi:10.1371/journal.pone.008265024324816
   PubMed Web of Science ®Google Scholar
• KimY, JaeE, YoonM. Influence of androgen receptor expression on the survival outcomes in breast cancer: a meta-analysis. J Breast Cancer. 2015;18(2):134–142. doi:10.4048/jbc.2015.18.2.13426155289
   PubMed Web of Science ®Google Scholar
• HilbornE, GacicJ, FornanderT, NordenskjöldB, StålO, JanssonA. Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer. Br J Cancer. 2016;114(3):248–255. doi:10.1038/bjc.2015.46426742006
   PubMed Web of Science ®Google Scholar
• AsanoY, KashiwagiS, OnodaN, et al. Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer. Br J Cancer. 2016;114(1):14–20. doi:10.1038/bjc.2015.43426757422
   PubMed Web of Science ®Google Scholar
• BaeSY, NamSJ, JungY, et al. Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer. Breast Cancer Res Treat. 2018;172(2):437–444. doi:10.1007/s10549-018-4928-230132220
   PubMed Web of Science ®Google Scholar
• Fernández-CuestaL, OakmanC, Falagan-LotschP, et al. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 Phase III trial. Breast Cancer Res. 2012;14(3):R70. doi:10.1186/bcr317922551440
   PubMed Web of Science ®Google Scholar
• CoatesAS, MillarEK, O’TooleSA, et al. Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Res. 2012;14(6):R143. doi:10.1186/bcr334823127292
   PubMed Web of Science ®Google Scholar
• LaraJF, ThorAD, DresslerLG, et al. p53 expression in node-positive breast cancer patients: results from the cancer and leukemia group B 9344 trial (159905). Clin Cancer Res. 2011;17(15):5170–5178. doi:10.1158/1078-0432.CCR-11-048421693655
   PubMed Web of Science ®Google Scholar
• BlagosklonnyMV. Loss of function and p53 protein stabilization. Oncogene. 1997;15(16):1889–1893. doi:10.1038/sj.onc.12013749365234
   PubMed Web of Science ®Google Scholar
• ThorAD, MooreDH II, EdgertonSM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992;84(11):845–855. doi:10.1093/jnci/84.11.8451317462
   PubMedGoogle Scholar
• PetitjeanA, AchatzMIW, Borresen-DaleAL, HainautP, OlivierM. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26(15):2157–2165. doi:10.1038/sj.onc.121030217401424
   PubMed Web of Science ®Google Scholar
• da SilvaJL, Cardoso NunesNC, IzettiP, de MesquitaGG, de MeloAC. Triple negative breast cancer: A thorough review of biomarkers. Crit Rev Oncol Hematol. 2020;145:102855. doi:10.1016/j.critrevonc.2019.10285531927455
   PubMed Web of Science ®Google Scholar